Posts

Showing posts from December, 2022

4 causes of vaginal yellow discharge - Insider

Image
Normal vaginal discharge is odorless and clear or white in color.  Yellow discharge could be a sign of a condition like chlamydia, cervical cancer, or trichomoniasis. If you have yellow vaginal discharge, schedule an appointment with an OB-GYN to determine the cause. Vaginal discharge is normal and typically clear, white, and odorless, says Peace Nwegbo-Banks, MD, an OB-GYN at Serenity Women's Health & Med Spa.   However, discharge that is a different color like yellowish-green or accompanied by a fishy odor may be a sign of the following underlying conditions. 1. Pelvic Inflammatory Disease Pelvic inflammatory disease is an infection that occurs when bacteria travels from the vagina to the uterus, fallopian tubes and ovaries. ...

What's the State of HIV Cure Research as 2022 Comes to an End? - The Body

Image
It seems as though a day did not go by in 2022 when we didn't see a headline suggesting that A BIG HIV CURE BREAKTHROUGH was right around the corner. So many early trials seem to be in play. And of course, we learned about the "New York patient," the third known person to be cured of HIV via stem-cell transplantation in the course of treatment for cancer. But, as you might imagine, it's never as simple as newspaper headlines make it out to be. Now, that's not to say that nothing hopeful has happened—but the picture is still complicated. To help explain where things stand in cure research and why these trials are so important, TheBody spoke with Richard Jefferys―the basic science, vaccines, and Cure Project director of Treatment Action Group. Tim Murphy: Hi, Richard! Thank you as ever for chatting with us. So, blunt question to start: What's the state of cure research? As vibrant as headlines often suggest? Richard Jefferys: There's some encourag...

Syphilis on the verge of tripling in Yucatan this year - The Yucatan Times

Image
In Yucatan, syphilis is on the verge of tripling, since only last week a case was confirmed every 12 hours, the highest figure in two months, revealed the federal Ministry of Health. So far this year, 412 accumulated confirmed cases of this Sexually Transmitted Disease (STD) have already been detected, so there is an increase of 176.51 percent compared to the same period in 2021, when the sum was 149 infected. Even, it already surpassed the total recorded during the two previous years, since in 2020, the total was 133 cases, while 2021 closed with 171 infected. In terms of gender, the pathology affected 302 men, 73.3 percent, and 110 women, 26.7 percent. Yucatan ranked 16th in the national incidence table, with 2.76 percent of the total number of cases in the country, and at the regional level, the problem is greater in Quintana Roo, where there are 825 positive cases, 5.53 percent, while in Campeche there are 113 confirmed cases, 0.75 percent. The epi...

FDA Approves Lenacapavir for HIV Treatment - Contagionlive.com

Image
This morning the FDA announced the approval of the antiretroviral Sunlenca (lenacapavir), which is indicated for adult patients living with HIV, whose infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations. "Today's approval ushers in a new class of antiretroviral drugs that may help patients with HIV who have run out of treatment options," Debra Birnkrant, MD, director of the Division of Antivirals in the FDA's Center for Drug Evaluation and Research, said in a statement. Lenacapavir is the first of a new class of therapies called capsid inhibitors to be FDA-approved for treating HIV. This antiretroviral works by blocking the HIV-1 virus' protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle. Treatment Protocol Lenacapavir's starting protocol is for patients to be given as oral tablets and subcutaneous injections, followed by maintenance...

Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More - Yahoo Finance

Image
The biotech sector was in focus with many important pipeline and regulatory updates. Collaboration deals were also in focus. Recap of the Week's Most Important Stories : Gilead's HIV Drug Approval :  Gilead Sciences, Inc . GILD announced that the FDA has approved lenacapavir in combination with other antiretroviral(s) (ARV) under the brand name Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug-resistant (MDR) HIV-1 infection. The approval of this new, twice-yearly treatment option for adults with HIV that is not adequately controlled by their current treatment regimen will boost Gilead's strong HIV franchise. Sunlenca, a first-in-class, long-acting HIV capsid inhibitor, has a multi-stage mechanism of action distinguishable from other currently approved classes of antiviral agents.  It is the only HIV treatment option administered twice yearly and thus will have an advantage over other existing treat...

On World AIDS Day, Canada must lead the way in combating HIV-AIDS - The Conversation Indonesia

Dec. 1 marks World AIDS Day. As researchers focused on fighting the HIV-AIDS epidemic, we are increasingly concerned all the progress made in the fight against the virus is at risk. In 1996, the first remarkable breakthrough against the HIV-AIDS epidemic came with the novel combination of drugs that became known as Highly Active Antiretroviral Therapy (HAART). For the first time, HAART was able to stop viral replication and render the virus undetectable in blood and bodily fluids, and consequently promote immune reconstitution. This in turn would prevent an HIV infection from developing into AIDS, significantly reducing premature deaths. Treatment as prevention The next major breakthrough came in the early 2000s. Through close monitoring of the epidemic in British Columbia, our research documented that HIV infected individuals who have consistent viral suppression with HAART are virtually unable to transmit the infection. This led us to recommend initiating HAART immedi...

Oscillating Positive Expiratory Pressure (OPEP) Market to Reach the value of USD 3,412.89 Mn by Forecast 2028 - EIN News

Image
Oscillating Positive Expiratory Pressure (OPEP) Market Oscillating Positive Expiratory Pressure (OPEP) Market is segmented on the basis of product type, indication and distribution channel PUNE, MAHARASHTRA, INDIA, December 28, 2022 /EINPresswire.com/ -- Being a proficient and comprehensive, "Oscillating Positive Expiratory Pressure (OPEP) Market" survey report puts a light on primary and secondary drivers, market share, leading segments, possible sales volume, and geographical analysis. This market research report contains thorough analysis of the market structure along with forecast of the various segments and sub-segments of the market. A numerous markets, marketing strategies, trends, future products and rising opportunities are taken into consideration while studying market and preparing this report. The chief areas covered in the wide ranging Oscillating Positive Expiratory Pressure (OPEP) market report include market definition, ...

Virological failure among people living with HIV receiving second ... - BMC Infectious Diseases

Image
Our cross-sectional study found that around one-sixth of participants met criteria for VF on second-line ART at a large tertiary ART center in western India. In addition, our analysis identified significant associations between VF and lower time-updated CD4 count (≤ 350 cells/mm 3 ), present OI and low weight (< 51 kg). Overall, this study adds to the limited evidence on second-line VF and associated factors in India. The prevalence of VF in our study population is consistent with that reported in the only other study from north India on second-line ART associated VF [3]. However, our estimate was obtained using a larger sample size from a different geographical region in India with higher HIV prevalence. Additionally, compared to the study from north India that included data only till 2012, the data we use is updated to 2015. Our prevalence estimate is also consistent with reports of VF from other LMICs, although varying definitions of VF across studies, makes it chall...

STIs With Flu-Like Symptoms - STDs - Verywell Health

Image
If you have flu-like symptoms, it could be from the flu (influenza), a similar viral illness, or a sexually transmitted infection (STI), also called a sexually transmitted disease (STD). STIs are transmitted through direct contact, usually (but not always) sexual in nature. Many exist, and each has unique symptoms. Common STIs that cause flu-like symptoms include: This article will review flu-like symptoms and list the STIs that can cause them. It will also detail other STI symptoms and explain how to tell the difference between the flu and STIs. Jasmin Merdan / Getty Images Flu-Like STI Symptoms The flu is a respiratory illness caused by the influenza virus. Influenza A and influenza B are common types of influenza that share many of the same symptoms. Primary flu symptoms include cough, sore throat, and nasal congestion (runny nose). Flu symptoms that are shared by STIs include: Fever Nausea and vomiting Headaches or body aches ...

Federal claims court rules in favor of Gilead in CDC Truvada patent ... - Endpoints News

Image
Gilead pulled a win last week in its on­go­ing patent bat­tle with the CDC over the HIV drug Tru­va­da for pre-ex­po­sure pro­phy­lax­is (PrEP). The US Court of Fed­er­al Claims ruled on Nov. 21 that the gov­ern­ment breached cer­tain agree­ments with Gilead by fail­ing to prompt­ly no­ti­fy the com­pa­ny of its patent ap­pli­ca­tions for Tru­va­da for PrEP, ac­cord­ing to doc­u­ments un­sealed on Wednes­day. The is­sue traces back to around 2004 when Tru­va­da won an ac­cel­er­at­ed ap­proval to treat HIV. Be­cause HIV is known to de­vel­op re­sis­tance to ther­a­py, pa­tients at the time were of­ten re­quired to take more than one drug at a time. Tru­va­da com­bines Gilead's pri­or HIV drugs, Emtri­va and Viread, mak­ing life eas­i­er for pa­tients who were tak­ing sep­a­rate pills dai­ly. Short­ly af­ter, the CDC and Gilead struck up a part­ner­ship to re­search Tru­va­da's use as a pre­ven­ta­tive mea­sure pri­or to ex­po­sure. The duo inked mul­ti­ple ma­te­r­i­al tr...

HIV in women: what you should know - Patient.info

Image
How common is HIV in women? Out of the 38.4 million people living with HIV (human immunodeficiency virus) worldwide in 2021, 54% were women and girls 1 . Yet, the HIV epidemic among women is often overlooked - the focus tending to fix on these high-risk groups: Men who have sex with men. Sex workers and their clients. People who inject drugs. Transgender people and their sexual partners. These groups have a significantly higher chance of catching HIV because of the sexual activities they engage in. The risk of HIV in women cannot be defined by a particular high-risk activity, but there are certain risk factors that make many girls and women around the world more vulnerable to this sexually transmitted infection (STI). How does location affect HIV in women? The majority of people living with HIV are in low-to-middle income countries. This is true for both men and women, but for women, living in these regions is associated with a much higher risk of HIV compared to men. In 2021, more tha...